风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金净值变化引致的投资风险，由投资人自行负担。基金的过 往业绩及其净值高低并不预示其未来业绩表现，基金管理人管理的其他基金的业绩不构成对本基金业绩 表现的保证。投资人购买基金，既可能按其持有份额分享基金投资所产生的收益，也可能承担基金投资 所带来的损失。投资人应当认真阅读《基金合同》《招募说明书》等基金法律文件，全面认识本基金的 风险收益特征和产品特性，并根据自身的投资目的、投资期限、投资经验、资产状况等判断基金是否和 投资人的风险承受能力相适应，理性判断市场，谨慎做出投资决策。本材料中相关信息来源于基金管理 人认为可靠的公开资料，相关观点、评估和预测仅反映当前的判断，后续可能有所变化。本材料所含任 何市场观点的内容皆基于相应的假设条件，而任何假设条件都可能随时发生变化。基金管理人不承诺、 不保证任何具有预测性质的市场观点必然得以实现。材料中提及的个股不构成投资推荐或建议。ETF基 金的二级市 ...

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index (HSSCPB) decreased by 1.40% as of February 5, 2026, with mixed performance among constituent stocks [1] - Notable gainers included Nocera Healthcare up 3.87%, Four Seasons Pharmaceutical up 3.14%, and Heng Rui Medicine up 2.77%, while MIRXES-B led the decline down 9.12% [1] - The Hong Kong Innovative Drug ETF (520690) fell by 1.20%, with a latest price of 0.82 yuan, but showed a 2.97% increase over the past month as of February 4, 2026 [1] Group 2 - As of January 31, 2026, 283 pharmaceutical stocks disclosed their 2025 earnings forecasts, with 160 stocks expected to see year-on-year profit growth, highlighting a positive trend in the innovative drug sector [2] - Sino Medical emerged as the "profit growth king" in A-shares with a forecasted increase of over 32 times, while WuXi AppTec is expected to achieve a record net profit of 19.151 billion yuan [2] - The demand for weight loss drugs remains strong, with Eli Lilly reporting a 43% year-on-year revenue increase to $19.29 billion in Q4, exceeding market expectations [2] Group 3 - Donghai Securities indicated that the innovative drug sector is entering a phase of accelerated profit realization, driven by rapid commercialization of products and business development collaborations [3] - The performance of the innovative drug sector validates the effectiveness of the domestic innovative drug business model, with core products supported by medical insurance driving growth [3] - The Hong Kong Innovative Drug ETF has seen continuous net inflows, totaling 16.3621 million yuan over three days, with a maximum single-day inflow of 8.9766 million yuan [3]